[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639865":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":20,"armGroups":27,"interventions":34,"overallOfficials":20,"centralContacts":39,"locations":45,"responsibleParty":62,"collaborators":64,"id":67,"slug":20,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":20,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":20,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":48,"whyStopped":20,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"SmartNuclide Biopharma","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":20},[9,13,16,18],{"measure":10,"description":11,"timeFrame":12},"The safety and tolerability profile of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.","Occurrence of AE\u002FSAE according to CTCAE 5.0","1 week",{"measure":14,"description":15,"timeFrame":12},"CLDN18.2-targeting ability of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer.","SUVmax of tumors",{"measure":14,"description":17,"timeFrame":12},"SUVmean of tumors",{"measure":14,"description":19,"timeFrame":12},"Correlation of tumor uptakes and Immunohistochemistry",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE",[28],{"label":29,"type":30,"description":31,"interventionNames":32},"Group","EXPERIMENTAL","68Ga-NODAGA-SNA006",[33],"Drug: 68Ga-NODAGA-SNA006",[35],{"type":36,"name":31,"description":37,"armGroupLabels":38,"otherNames":20},"DRUG","Administration",[29],[40],{"name":41,"role":42,"phone":43,"phoneExt":20,"email":44},"Dong Dai, Doctor","CONTACT","022-23340123","1014481959@qq.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Tianjin Medical University Cancer Institute and Hospital","RECRUITING","Tianjin","Tianjin Municipality","300000","China","CN",{"type":55,"coordinates":56},"Point",[57,58],117.17667,39.14222,{"lat":58,"lon":57},[61],{"name":47,"role":42,"phone":20,"phoneExt":20,"email":20},{"type":63,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[65],{"name":47,"class":66},"OTHER","100639865",false,"NCT07597772","Preliminary Trial of SNA014 for Pancreatic Cancer","A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET\u002FCT for the Imaging of Pancreatic Cancer","Inclusion Criteria:\n\n1. Aged between 18 and 75 years (inclusive);\n2. Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);\n3. Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;\n4. Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);\n5. Pathology test results from within the past year;\n\nExclusion Criteria:\n\n1. Patients with other clearly diagnosed malignant tumours;\n2. Patients with uncontrolled severe infections, or those with other serious comorbidities;\n3. Patients with a life expectancy of ≤3 months;\n4. Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;\n5. Patients deemed unsuitable for participation in this study by the investigator.","ALL","18 Years","75 Years",{"count":77,"type":78},12,"ESTIMATED","INTERVENTIONAL",[81],"EARLY_PHASE1","68Ga labeled Claudin 18.2 contrast agent combined with PET\u002FCT for pancreatic cancer",[84],"Pancreatic Cancer",[86,87,88],"Pancreatic cancer","68Ga","Claudin 18.2","2026-05-13",{"date":91,"type":92},"2026-05-19","ACTUAL",{"date":94,"type":92},"2025-10-01",{"date":96,"type":78},"2026-07-01",{"name":5,"class":6},1]